Summary
AbbVie Inc. (ABBV) announced an expansion of its Board of Directors, increasing its size from eleven to thirteen members. This strategic move involves the appointment of two new independent directors: Jennifer Davis, CEO of Health Care at Procter & Gamble, and Susan Quaggin, Professor and Chair of Medicine at Northwestern University Feinberg School of Medicine. The addition of these directors, who bring extensive experience in consumer health and medical leadership respectively, is intended to enhance the Board's expertise and oversight capabilities. Ms. Davis has been appointed to the Nominations and Governance Committee, while Dr. Quaggin will serve on the Public Policy and Sustainability Committee. Both directors have been deemed independent by the Board according to NYSE and AbbVie's internal guidelines. Investors can expect these appointments to contribute to the company's strategic direction and governance, leveraging their distinct professional backgrounds to further AbbVie's long-term objectives.
Key Highlights
- 1AbbVie Inc. expanded its Board of Directors from eleven to thirteen members.
- 2Jennifer Davis, CEO of Health Care at Procter & Gamble, was appointed as a Class II director.
- 3Susan Quaggin, Professor and Chair of Medicine at Northwestern University, was appointed as a Class III director.
- 4Both new directors have been determined to be independent.
- 5Jennifer Davis joins the Nominations and Governance Committee.
- 6Susan Quaggin joins the Public Policy and Sustainability Committee.
- 7These appointments are effective as of October 11, 2023.